Patients with schizophrenia often stop taking their medications, so long-acting injectable antipsychotics (LAIs) are potentially good ways to make sure these patients have some medication in their systems over the long term.

After reading these articles, you should be able to…

Choosing the “right” treatment for a given patient involves a large number of factors, including personal preference—both the clinician’s and the patient’s. Is there a better way?

Assurex Health recently sent me an email inviting me to dine at Legal Seafood to learn about “Clinical Applications of Psychiatric Pharmacogenetics.” I didn’t go, but increasingly I am hearing from colleagues about their experiences at these dinner programs: “What do you think about this GeneSight test? The data looked pretty impressive at this dinner.”

Get advice on how to evaluate the methodology of biomarker studies in an interview with James Coyne, PhD, clinical health psychologist, professor emeritus of in the psychiatry with University of Pennsylvania and professor of health psychology, University of Groningen, the Netherlands.

After reading these articles, you should be able to…

There are plenty of ways that we use technology in psychiatric practice these days—including e-prescribing, electronic health records, referring patients to websites for psychoeducation, etc. But when was the last time you referred a patient to their computer for psychotherapy? Well, it may be time to consider it.

Get advice on how you can become a top-performing clinician, including how to put processes in place to consistently get feedback from your patients, in an interview with Scott D. Miller, PhD, found and director of the International Center for Clinical Excellence.

Repetitive transcranial magnetic stimulation (rTMS) is approved by the US Food and Drug Administration (FDA) for treatment resistant depression (TRD), and presumably works by modulating brain circuitry. A new meta-analysis focuses specifically on using rTMS as augmentation to antidepressants in patients with TRD.

Lisdexamfetamine (Vyvanse), a stimulant approved for treating kids and adults with ADHD, is the first drug approved by the US Food and Drug Administration (FDA) for treating adults with binge-eating disorder (BED).